Loading
Co-invented the CAPP-Seq method for reading tumour DNA in blood and used it to track lymphoma and lung cancer.
Ash Alizadeh is Professor of Medicine (Oncology) at Stanford University, within the Stanford Cancer Institute. An oncologist and computational biologist, he co-developed CAPP-Seq and phased variant enrichment for ultrasensitive circulating tumour DNA detection, applied to minimal residual disease in lymphoma and lung cancer, and led early work on tumour cell-of-origin classification in diffuse large B-cell lymphoma. His papers include a Nature Medicine report of an ultrasensitive method for quantitating circulating tumour DNA with broad patient coverage and the Nature paper identifying distinct types of diffuse large B-cell lymphoma by gene expression profiling. He continues to work on liquid biopsy and molecular residual disease testing.
| Title | Journal | Year |
|---|---|---|
| An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage | Nature Medicine | 2014 |
| Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Nature | 2000 |
Shares Stanford Health Care / Stanford Cancer Institute, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).